Fulcrum Therapeutics (Fulcrum Therapeutics) Cash-to-Debt : 21.83 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Fulcrum Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Fulcrum Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 21.83.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Fulcrum Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Fulcrum Therapeutics's Cash-to-Debt or its related term are showing as below:

FULC' s Cash-to-Debt Range Over the Past 10 Years
Min: 15.12 Med: 1934.26 Max: No Debt
Current: 21.83

During the past 7 years, Fulcrum Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 15.12. And the median was 1934.26.

FULC's Cash-to-Debt is ranked better than
65.56% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs FULC: 21.83

Fulcrum Therapeutics Cash-to-Debt Historical Data

The historical data trend for Fulcrum Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Fulcrum Therapeutics Cash-to-Debt Chart

Fulcrum Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1,934.26

6,642.00

No Debt

15.12

21.83

Fulcrum Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															15.12	23.27	22.88	22.37	21.83

Competitive Comparison of Fulcrum Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Fulcrum Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulcrum Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fulcrum Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Fulcrum Therapeutics's Cash-to-Debt falls into.

Fulcrum Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Fulcrum Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	236.221	/	(2.192	+	8.629)
	=	21.83

Fulcrum Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	236.221	/	(2.192	+	8.629)
	=	21.83

Fulcrum Therapeutics (NAS:FULC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Fulcrum Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Fulcrum Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulcrum Therapeutics (Fulcrum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fulcrum Therapeutics Inc (NAS:FULC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Landsdowne Street, Cambridge, MA, USA, 02139

Website

https://www.fulcrumtx.com

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company's proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

Executives

Alan A Musso	officer: Chief Financial Officer	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alex Sapir	director, officer: See Remarks	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Greg Tourangeau	officer: Controller	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J Gould	director, officer: President & CEO	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Santiago Arroyo	officer: Chief Medical Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Hayes Melvin H. Iii	officer: Chief Operating Officer	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Esther Rajavelu	officer: Chief Financial Officer	26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sonja Banks	director	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bryan Stuart	officer: Chief Operating Officer	C/O CIVITAS THERAPEUTICS, INC., 190 EVERETT AVENUE, CHELSEA MA 02150
Christopher Moxham	officer: Chief Scientific Officer	26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Peter G. Thomson	officer: VP Finance & Accounting	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139